Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cp 529,414
2. Cp 529414
3. Cp-529,414
4. Cp-529414
5. Cp529,414
6. Cp529414
1. 262352-17-0
2. Cp-529414
3. Cp 529414
4. Cp-529,414
5. (2r,4s)-4-((3,5-bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2h-quinoline-1-carboxylic Acid Ethyl Ester
6. Chembl479527
7. Ethyl (2r,4s)-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate
8. Ethyl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate
9. Ethyl (2r,4s)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate
10. Chebi:49203
11. 4n4457mv2u
12. Torcetrapib [usan]
13. 1(2h)-quinolinecarboxylic Acid, 4-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, Ethyl Ester, (2r,4s)-
14. (2r,4s)-ethyl 4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate
15. (2r,4s)-rel-ethyl 4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate
16. 262350-59-4
17. Torcetrapib (usan/inn)
18. Torcetrapib [usan:inn]
19. Unii-4n4457mv2u
20. Torcetrapib [mi]
21. Torcetrapib [inn]
22. Torcetrapib [mart.]
23. Schembl49081
24. Torcetrapib [who-dd]
25. Mls006010664
26. Torcetrapib (cp-529414)
27. Torcetrapib, >=98% (hplc)
28. Dtxsid20180873
29. Ex-a081
30. Amy24146
31. Zinc8214714
32. Bdbm50312718
33. Mfcd09260777
34. S2792
35. Akos024458018
36. Ccg-270197
37. Cs-3497
38. Db06281
39. Ncgc00346703-01
40. Ncgc00346703-03
41. 1(2h)-quinolinecarboxylic Acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl) (methoxycarbonyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, Ethyl Ester, (2r,4s)-
42. Ac-35371
43. As-16356
44. Ethyl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonyl-amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate
45. Hy-12089
46. Smr004701649
47. D06195
48. A818334
49. Sr-01000944945
50. Q7825530
51. Sr-01000944945-1
52. W-202112
53. Brd-k55675242-001-03-0
54. (2r, 4s)-4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2h-quinoline-1-carboxylic Acid Ethyl Ester
55. (2r,4s)-4-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-1-carboxylic Acid Ethyl Ester
56. (2r,4s)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h
57. 0rp
58. 1(2h)-quinolinecarboxylic Acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl) (methoxycarbonyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, Ethyl Ester, (2r,4s)-
Molecular Weight | 600.5 g/mol |
---|---|
Molecular Formula | C26H25F9N2O4 |
XLogP3 | 7 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 13 |
Rotatable Bond Count | 7 |
Exact Mass | 600.16706074 g/mol |
Monoisotopic Mass | 600.16706074 g/mol |
Topological Polar Surface Area | 59.1 Ų |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 889 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in peripheral vascular disease and hyperlipidemia.
Anticholesteremic Agents
Substances used to lower plasma cholesterol levels. (See all compounds classified as Anticholesteremic Agents.)
Torcetrapib is an inhibitor of cholesteryl ester-transfer protein (CETP) that increases high-density lipoprotein (HDL) cholesterol levels. The drug increases HDL-cholesterol and apolipoprotein A-I levels and decreases LDL-cholesterol and apolipoprotein B levels. The effect is showed in monotherapy and when administered in combination with statins.
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?